ClinicalTrials.gg
CompletedNCT07948096No acronymUpdated Nov 19, 2026

Comparison of Ibuprofen and Pregabalin With Control as Preemptive Analgesia in Spine Surgery

A Phase 4 interventional study of Pregabalin and Ibuprofen (400 mg) in Post Operative Pain, Spine Surgery and Preemptive Analgesia, sponsored by Universitas Indonesia. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Universitas Indonesia · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jun 2026, registered Nov 2026).
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 66 studies testing pregabalin in Pain, Postoperative — 7 open to participants now, 7 under way, 1 of them phase 3. Pregabalin · Pain, Postoperative.

Enrollment
48th of 66
65 · median 90
Started
2026
with 2 others
Phase 4
22 of 66
3 open now
Registered
66th of 66
by date

Among the 66 studies testing pregabalin in Pain, Postoperative, this one is the 48th largest by enrollment, is one of 3 that started in 2026, is one of 22 in phase 4, and was the 66th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,240 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

7 of the 66 studies testing pregabalin in Pain, Postoperative are open now, in 5 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 675 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 328 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing pregabalin in Pain, Postoperative, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if combining pregabalin and ibuprofen, given before surgery (preemptive analgesia), works to reduce pain after spine surgery in adults aged 18-60 years. The main questions it aims to answer are:

Does the combination of pregabalin and ibuprofen lower postoperative pain scores (VAS) over the first 24 hours after surgery? Does it lengthen the time until a patient first needs additional pain relief (morphine through a patient-controlled analgesia, or PCA, device)? Does it reduce the total amount of additional morphine needed in 24 hours? Does it shorten the length of hospital stay?

Researchers will compare the combination of pregabalin and ibuprofen to a control (a sugar capsule and 0.9% saline, which contain no active drug) to see if the combination works to treat pain after spine surgery. All participants will also receive the standard pain medicines paracetamol and ketorolac.

Participants will:

Take pregabalin 150 mg by mouth 2 hours before surgery and receive ibuprofen 400 mg by vein 30 minutes before anesthesia induction, or take a sugar capsule and receive 0.9% saline at the same times Undergo elective spine surgery under general anesthesia Use a PCA morphine device after waking from anesthesia whenever they feel pain (VAS above 4) Rate their pain on a visual analogue scale (VAS) at hours 0, 1, 2, 4, 8, 12, and 24 after surgery Be followed until hospital discharge

Read the detailed description

Background and Rationale

Spine surgery is associated with substantial postoperative pain. Reports describe chronic pain in about 40% of patients after spinal fusion, and a systematic review found that nearly 80% of patients experience postoperative pain after spine surgery, with 86% of them reporting moderate to severe pain. Uncontrolled pain can delay mobilization and prolong hospital stay. At Cipto Mangunkusumo National General Hospital (RSCM), there is no clinical practice guideline for postoperative pain management after spine surgery. Patients routinely receive the same regimen of paracetamol and ketorolac, yet pain scores peak around 3 to 4 hours after surgery at VAS 4 to 5.

Preemptive analgesia aims to reduce postoperative pain by giving analgesics before the surgical stimulus, limiting peripheral and central sensitization. Pregabalin acts centrally by binding the alpha-2-delta subunit of voltage-gated calcium channels, reducing release of excitatory neurotransmitters. Ibuprofen acts peripherally by inhibiting cyclooxygenase and reducing prostaglandin synthesis. Because the two drugs act through different pathways, their combination is expected to provide multimodal analgesia that is better than either drug alone. Evidence for this specific combination in spine surgery is limited, and it has not been evaluated at RSCM.

Hypothesis

Preemptive pregabalin plus ibuprofen is better than control in lowering postoperative pain scores, lengthening the time to the first additional analgesic, reducing the total additional analgesic requirement, and shortening hospital stay after spine surgery.

Study Design

This is a single-blind (participant-masked), randomized controlled trial conducted at RSCM, Jakarta, Indonesia. Participants are recruited by consecutive sampling and allocated by simple randomization. The random sequence is generated by an assistant who is not involved in the study, and allocations are kept in sealed, opaque envelopes opened by the anesthesia resident one hour before surgery. The sample size was calculated at 28 participants per group, and with an additional 20% for dropouts, 34 per group (68 in total) were planned.

All participants receive standardized general anesthesia and the same routine postoperative analgesia (paracetamol and ketorolac). After extubation, each participant is given a patient-controlled analgesia (PCA) device containing morphine 0.5 mg/mL, with a 15-minute lock-out interval, to be used when pain exceeds VAS 4. Antiemetic and antihistamine drugs and resuscitation equipment are available to manage morphine-related adverse effects. Pain is assessed with a visual analogue scale (VAS), supported by a pain-scale card to help participants. The time to first additional analgesia is measured from extubation to the first PCA press, and the total additional analgesia is the cumulative morphine dose delivered by the PCA over 24 hours. Length of stay is measured from the end of surgery to discharge.

Statistical Analysis

Data are analyzed with SPSS. Normality is tested with the Shapiro-Wilk test. Normally distributed data are presented as mean ± standard deviation and compared with the unpaired t-test; non-normally distributed data are presented as median (minimum-maximum) and compared with the Mann-Whitney test. Categorical data are compared with the chi-square test, or Fisher's exact test when expected counts are below 5. A p-value below 0.05 is considered statistically significant.

Ethics

The study was approved by the Health Research Ethics Committee of the Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo Hospital. Written informed consent is obtained from all participants after explanation of the study's aims, procedures, benefits, and risks.

03

Conditions studied

  • Post Operative Pain
  • Spine Surgery
  • Preemptive Analgesia
  • Post Operative Opioid Consumption

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 60 years
  • (ASA) physical status 1 to 3
  • Scheduled for elective spine surgery under general anesthesia

Exclusion criteria

Exclusion Criteria:

  • Refuses to participate in the study
  • Allergy to the analgesic agents used in the study
  • Postoperative care in the intensive care unit and not extubated after surgery
  • Renal impairment or hemostasis disorder
  • Severe cardiac or pulmonary comorbidity
  • Peptic ulcer or gastrointestinal bleeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Pregabalin+Ibuprofen

    Pregabalin 150 mg orally 2 hours before surgery and ibuprofen 400 mg intravenously 30 minutes before anesthesia induction. All participants also receive standard paracetamol and ketorolac, and a morphine PCA after extubation.

    Drug: Pregabalin · Drug: Ibuprofen (400 mg)

  • Placebo comparator
    Control

    Sugar capsule orally 2 hours before surgery and 0.9% sodium chloride intravenously 30 minutes before anesthesia induction. All participants also receive standard paracetamol and ketorolac, and a morphine PCA after extubation.

    Other: Placebo

Interventions

  • 150 mg orally, single dose, 2 hours before surgery.

  • DrugIbuprofenStudies of IbuprofenIbuprofen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    400 mg intravenously, single dose, 30 minutes before anesthesia induction.

  • OtherPlacebo

    Sugar capsule orally 2 hours before surgery and 0.9% sodium chloride intravenously 30 minutes before anesthesia induction.

06

What researchers measure

Primary outcomes

  1. Postoperative pain score (Visual Analogue Scale)

    Pain intensity measured with the Visual Analogue Scale (VAS), 0 to 10, where 0 is no pain and 10 is the worst pain imaginable. Higher scores mean worse pain. Assessed at hour 0 (after extubation), 1, 2, 4, 8, 12, and 24 after the end of surgery, and compared between the pregabalin + ibuprofen group and the control group

    Time frame: 0, 1, 2, 4, 8, 12, and 24 hours after the end of surgery

  2. Time to first additional analgesia (minutes from extubation to first PCA morphine press)

    Time from extubation to the first press of the patient-controlled analgesia (PCA) device containing morphine 0.5 mg/mL, used as additional analgesia when the patient reports pain (VAS above 4). The PCA has a 15-minute lock-out interval. Compared between the pregabalin + ibuprofen group and the control group

    Time frame: Up to 24 hours after extubation

  3. Total additional analgesia (cumulative PCA morphine dose, mg)

    Total dose of morphine (mg) delivered by the patient-controlled analgesia (PCA) device (0.5 mg/mL, 15-minute lock-out) from extubation until 24 hours afterward, used as additional analgesia when pain exceeds VAS 4. Compared between the pregabalin + ibuprofen group and the control group.

    Time frame: 24 hours after extubation

  4. Length of hospital stay (days from end of surgery to discharge)

    Number of days from the end of surgery until the patient is allowed to go home by the surgeon. Compared between the pregabalin + ibuprofen group and the control group.

    Time frame: From end of surgery until hospital discharge, assessed up to 30 days

  5. Incidence of significant pain (VAS > 3 at any time point)

    Proportion of participants with significant pain, defined as a VAS score above 3 at one or more of the seven measurement points (hours 0, 1, 2, 4, 8, 12, and 24 after the end of surgery). Compared between the pregabalin + ibuprofen group and the control group.

    Time frame: 0 to 24 hours after surgery

07

Study locations

1 site
  • Dr. Cipto Mangunkusumo National General Hospital
    Jakarta Pusat, 10430, Indonesia
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2026 to primary completion in Oct 2026, 4 months.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 4 months is below that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartActual
Jun 9, 2026
Primary completionActual
Oct 21, 2026
CompletionActual
Oct 21, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07948096
Lead sponsor
Universitas Indonesia
Responsible party
Pryambodho Pryambodho (Lecturer, Anesthesiologist, Department of Anesthesiology and Intensive Care, Faculty of Medicine, Universitas Indonesia, Universitas Indonesia) — Principal investigator
First posted
Nov 19, 2026
Start date
Jun 9, 2026
Primary completion
Oct 21, 2026
Completion
Oct 21, 2026
Last update
Nov 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pregabalin · Ibuprofen

Start the discussion